» Articles » PMID: 38375096

Sleep Quality Among Non-hospitalized COVID-19 Survivors: a National Cross-sectional Study

Overview
Specialty Public Health
Date 2024 Feb 20
PMID 38375096
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Insomnia is a common symptom after COVID-19 infection; however, its current evidence was among hospitalized COVID-19 patients. This study aimed to assess the prevalence of insomnia and identify its association with depression and anxiety among non-hospitalized COVID-19 recovered population.

Methods: We conducted a cross-sectional online survey of 1,056 COVID-19 survivors within 6 months of initial COVID-19 infection and retrieved did not require hospitalization. The Insomnia Severity Index, and Depression Anxiety and Stress Scale-14 were used. Multivariate logistic regression was used to examine the associations between depressive and anxiety score, and participants' insomnia level.

Results: The prevalence of insomnia was 76.1%, and among those, 22.8% of participants scored for severe insomnia. One third of participants reported worse sleep quality, shorter sleep duration, and harder to fall asleep, half reported more awaken nights after COVID-19 infection. Participants with depressive (OR 3.45; 95%CI 1.87-6.34) or anxiety (OR 3.93; 95%CI 2.52-6.13) had significantly higher odds of developing insomnia. Other risk factors of insomnia included pre-existing chronic conditions and higher education level, while COVID-19 symptoms and duration were not significantly associated.

Conclusion: Our study highlights the substantial burden of insomnia among non-hospitalized COVID-19 survivors and the significant association of depression and anxiety on the development of this long-term effect of COVID-19. These findings underscore the need for comprehensive interventions that address both sychological and sleeping health in this population.

Citing Articles

Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primates.

Sauter K, Webb G, Bader L, Kreklywich C, Takahashi D, Zaro C bioRxiv. 2025; .

PMID: 40027795 PMC: 11870618. DOI: 10.1101/2025.02.18.638792.


Long-term gastrointestinal symptoms and sleep quality sequelae in adolescents after COVID-19: a retrospective study.

Yang W, Wang Q, Wang Y, Sun S, Shen Y, Yu L Front Public Health. 2024; 12:1323820.

PMID: 38835614 PMC: 11148350. DOI: 10.3389/fpubh.2024.1323820.

References
1.
Kwekkeboom K, Abbott-Anderson K, Cherwin C, Roiland R, Serlin R, Ward S . Pilot randomized controlled trial of a patient-controlled cognitive-behavioral intervention for the pain, fatigue, and sleep disturbance symptom cluster in cancer. J Pain Symptom Manage. 2012; 44(6):810-22. PMC: 3484234. DOI: 10.1016/j.jpainsymman.2011.12.281. View

2.
Neubauer D, Pandi-Perumal S, Spence D, Buttoo K, Monti J . Pharmacotherapy of Insomnia. J Cent Nerv Syst Dis. 2018; 10:1179573518770672. PMC: 5987897. DOI: 10.1177/1179573518770672. View

3.
Al-Aly Z, Xie Y, Bowe B . High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021; 594(7862):259-264. DOI: 10.1038/s41586-021-03553-9. View

4.
Buysse D . Insomnia. JAMA. 2013; 309(7):706-16. PMC: 3632369. DOI: 10.1001/jama.2013.193. View

5.
Ancoli-Israel S . The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness. Am J Manag Care. 2006; 12(8 Suppl):S221-9. View